The Role of Montelukast in Rhinitis and Sleep
The Role of Montelukast in Rhinitis and Sleep
Bio2RDF identifier
NCT00590772
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00590772
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
baseline [clinicaltrials_vocabulary:baseline]
brief summary [clinicaltrials_vocabulary:brief-summary]
The hypothesis is that ...... somnolence and
fatigue.
brief title [clinicaltrials_vocabulary:brief-title]
The Role of Montelukast in Rhinitis and Sleep
clinical result [clinicaltrials_vocabulary:clinical-result]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2009-01-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Montelukast is a once d ...... % on
a severity rating.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2007-12-26T00:00:00Z
firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]
2009-07-21T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2014-10-20T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00590772
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Phase 4- The Role of Monteluka ...... urbance and Daytime Somnolence
org study id [clinicaltrials_vocabulary:org-study-id]
IRB 2003-114
outcome [clinicaltrials_vocabulary:outcome]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
participant flow [clinicaltrials_vocabulary:participant-flow]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2009-01-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
Merck Grant #IISP ID# 20030
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2003-05-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2014-10-01T00:00:00Z
identifier
clinicaltrials:NCT00590772
title
The Role of Montelukast in Rhinitis and Sleep
@en